Bio-Path Investor Relations Material
Latest events
Q4 2023
Bio-Path
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Bio-Path Holdings Inc
Access all reports
Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused RNAi nano particle drug development company that operates in the United States. The Company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. Bio-Path Holdings, Inc. was founded in 2007 and is headquartered in Bellaire, Texas.
Latest articles
Puig's 2024 IPO: Paco Rabanne, Jean Paul Gaultier, and Beyond
Explore Puig's journey from its 1914 inception to a 2024 IPO, showcasing its growth, strategic acquisitions, and impact in the beauty and fashion industry.
15 Apr 2024
Alphabet's Unstoppable Rise: From Stanford to Global Tech Leader
Discover Alphabet's rise from a university project to a global tech leader, highlighting its growth, diversification, and visionary leadership.
15 Apr 2024
Companies That Had Their IPO in 2022: War, Inflation and Interest Rates
The stock market and IPO landscape in 2022 was marked by inflationary pressures, rate hikes, and war that heavily impacted the market sentiment.
15 Apr 2024
Ticker symbol
Country
🇺🇸 United States